Nuvectis Pharma (NASDAQ:NVCT) Earns Buy Rating from Analysts at Laidlaw
Laidlaw initiated coverage on shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) in a report released on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $19.00 price objective on the stock. Separately, HC Wainwright dropped their price objective on shares of Nuvectis Pharma from $21.00 to $11.00 and set a “buy” […]
Laidlaw initiated coverage on shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) in a report released on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $19.00 price objective on the stock. Separately, HC Wainwright dropped their price objective on shares of Nuvectis Pharma from $21.00 to $11.00 and set a “buy” […]
